ETNB
89bio, Inc.14.84
+0.00+0%
Oct 29, 4:00:02 PM EDT
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
2.20BP/E (TTM)
-Basic EPS (TTM)
-3.69Dividend Yield
0%Recent Filings
8-K
89bio merges with Roche
89bio completed its merger with Roche's subsidiary on October 30, 2025, after 60.49% of shares tendered in the offer expired the prior day, satisfying conditions without a stockholder vote. Shareholders received $14.50 cash per share plus a CVR for up to $6.00 more on milestones, while the company terminated its loan agreement with Parent covering obligations. Now Roche's wholly owned unit, 89bio delisted from Nasdaq, ending public trading. Change of control secured.
8-K
Roche acquires 89bio for $20.50 max
89bio agreed to be acquired by Roche Holdings on September 17, 2025, via a tender offer starting no later than October 1, 2025, for $14.50 per share in cash plus a non-tradeable CVR worth up to $6.00 upon pegozafermin milestones like first commercial sale by March 31, 2030. The deal, totaling up to $3.5 billion fully diluted, secures Roche's entry into MASH treatments while locking in immediate value for shareholders. Yet CVR payouts hinge on sales targets through 2035. Regulatory hurdles could delay closure.
10-Q
Q2 FY2025 results
89bio ramped up R&D spending in Q2 FY2025 ended June 30, 2025, posting a $111.5M net loss, up 132% y/y from $48.0M, driven by a $40M payment to BiBo for manufacturing facility construction and Phase 3 trial advances in MASH and SHTG programs. Operating expenses hit $115.8M, a 117% y/y jump, with no revenue yet as pegozafermin progresses toward topline data in 2026-2027. Cash and equivalents stood at $129.1M, bolstered by $561.2M total liquidity including marketable securities, funding operations for at least a year; a $35M term loan at 9.25% matures in 2028 with no near-term principal due. The $40M BiBo payment caps 89bio's exposure, securing commercial supply without further cost overruns. Warrants tied to undrawn loan tranches expired, simplifying the balance sheet. Yet regulatory hurdles loom large in MASH trials.
8-K
89bio Q2 loss widens on trials
89bio reported a Q2 2025 net loss of $111.5 million, up from $48.0 million last year, fueled by $103.9 million in R&D expenses from Phase 3 MASH trials and a $42.4 million manufacturing payment. Cash reserves stand at $561.2 million, funding operations through key readouts. Topline data from ENTRUST in SHTG arrives 1Q 2026. Yet trial delays could strain resources.
8-K
89bio annual meeting results
89bio, Inc. held its 2025 Annual Meeting on May 28, electing Martin Babler, Derek DiRocco, Ph.D., and Lota Zoth, C.P.A. as Class III directors amid mixed support—Babler garnered 104.8 million votes for, DiRocco just 63.5 million. Shareholders ratified KPMG LLP as auditors with near-unanimous approval and backed executive compensation on an advisory basis. Board continuity holds firm. Yet votes withheld signal scrutiny on leadership.
ALT
Altimmune, Inc.
5.03-0.25
BLTE
Belite Bio, Inc
149.13+6.60
ENDV
Endonovo Therapeutics, Inc.
0.00+0.00
FBLG
FibroBiologics, Inc.
0.24-0.02
IMA
ImageneBio, Inc.
6.25+0.08
INAB
IN8bio, Inc.
1.50-0.10
KALA
KALA BIO, Inc.
0.56-0.05
PEPG
PepGen Inc.
5.52+0.05
SGMT
Sagimet Biosciences Inc. - Seri
6.05+0.02
SLNO
Soleno Therapeutics, Inc.
49.50-0.45